In November, the FDA issued a warning to consumers telling them to immediately stop taking Limbrel until the agency completed an investigation into the reported rise of adverse events, such as drug-induced liver injury and hypersensitivity pneumonitis, a lung condition.
As of Nov. 21, the FDA received 194 reports of adverse events involving Limbrel. In a preliminary investigation, 30 of the events were found to be associated with the product. Since issuing that public warning on Nov. 21, the agency has received additional reports of liver and lung injuries in connection to the product.
Although Primus markets Limbrel as a medical food, since it is supposed to “address the metabolic process associated with osteoarthritis,” the FDA is now calling the product an “unapproved drug.” The agency can not force the company to recall the product.
More articles on supply chain:
Depomed slashes workforce by 40%, relocates headquarters following deal
Avanir Pharmaceuticals cuts 11% of workforce, including sales reps amid probe into marketing practices
FDA warns of a new product shortage worsened by Hurricane Maria: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
